Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (pSS) Who Complete Qualifying Efgartigimod pSS Studies

NCT06203457 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06203457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06203457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (pSS) Who Complete Qualifying Efgartigimod pSS Studies
Lead sponsor
argenx
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2023
Completion date
February 3, 2025
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome